Pfizer (NYSE:PFE) Stock Sees Heavy Call Option Buying

Pfizer Inc. (NYSE:PFE – Get Free Report) saw unusually large options trading activity on Thursday. Stock investors purchased 673,000 call options on the stock. This is an increase of approximately 584% compared to the average daily volume of 98,364 call options.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

  • Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
  • Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
  • Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
  • Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

Pfizer Stock Down 1.7%

PFE stock opened at $29.38 on Friday. Pfizer has a twelve month low of $23.62 and a twelve month high of $31.44. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The business’s 50-day simple moving average is $28.74 and its 200 day simple moving average is $26.90. The company has a market cap of $167.46 billion, a PE ratio of 10.06, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the firm posted $0.87 earnings per share. Pfizer’s revenue for the quarter was down .4% compared to the same quarter last year. On average, research analysts anticipate that Pfizer will post 3.03 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.9%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is presently 245.71%.

Institutional Trading of Pfizer

Several large investors have recently added to or reduced their stakes in PFE. Bank of America Corp DE purchased a new stake in Pfizer in the 2nd quarter worth approximately $1,049,602,000. BlackRock Inc. increased its stake in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after buying an additional 31,412,883 shares during the period. Nykredit A S acquired a new stake in shares of Pfizer during the second quarter worth $205,774,000. Assenagon Asset Management S.A. boosted its holdings in shares of Pfizer by 96.0% during the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock worth $286,609,000 after purchasing an additional 5,829,204 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after buying an additional 5,501,032 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Argus set a $40.00 price target on shares of Pfizer in a research report on Wednesday. JPMorgan Chase & Co. boosted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. BMO Capital Markets dropped their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Finally, Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Six equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $30.39.

View Our Latest Stock Report on Pfizer

About Pfizer

(Get Free Report)

Read More

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.